Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

73.74 -1.50 (-1.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 421,913
Open 75.04
Bid (Size) 73.74 (2)
Ask (Size) 73.80 (2)
Prev. Close 75.24
Today's Range 73.12 - 75.80
52wk Range 20.63 - 82.85
Shares Outstanding 43,573,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Top Healthcare Stocks to Buy With $100
You don't need a fortune to start investing. 
Via The Motley Fool
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+0.57%
+0.57%
1 Month
-8.08%
-8.08%
3 Month
+26.29%
+26.29%
6 Month
-1.50%
-1.50%
1 Year
+183.40%
+183.40%

More News

Read More
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics's Return On Capital Employed Overview
Via Benzinga
3 Growth Stocks to Buy and Hold
Via The Motley Fool
Expert Ratings for Axsome Therapeutics
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
Prediction: These 2 Stocks Could Double In the Next Year
Via The Motley Fool
2 Biotech Stocks That Could Help Set You Up for Life
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Bear Market Defying Stocks to Buy in May
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Via The Motley Fool
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
Via The Motley Fool
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
Via Investor's Business Daily
This Analyst Creates Bullish Pitch For Axsome Therapeutics On Increased Outlook For Its Depression Drug
Via Benzinga
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
Via The Motley Fool
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Via The Motley Fool
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage
Via Benzinga
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Via Investor's Business Daily
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Via InvestorPlace
NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc.
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.